More than two years after a government crackdown on corruption sent Macau gaming stocks tumbling, The Chinese government has unveiled yet another new regulation on the Macau gaming industry that has hit gaming stocks hard. The latest new law cut the daily ATM withdrawal limit in Macau from 10,000 patacas to 5,000 patacas, or roughly $626.
Unfortunately, transparency and predictability has never been one of the Chinese government's strong points. Wynn Resorts, Limited (NASDAQ: WYNN) CEO Steve Wynn said the government's behavior was "preposterous" when it kept operators in the dark about how many table games they would be allotted just weeks prior to opening billion-dollar new resorts. For the record, none of the major operators that have opened resorts in the past two years have received the table allotment they requested.
Although the U.S. gaming market likely doesn't have the kind of long-term growth potential that Macau does, U.S. casinos are doing just fine these days. In the current fiscal year, Las Vegas Strip revenue is trending about 6% ahead of last year, and other regions of the country are doing even better. For better or worse, U.S. stock investors likely won't have to worry about new regulations in the next four years under President-elect Trump.
Hot Casino Stocks To Invest In Right Now: Roche Holding AG (RHHBY)
Advisors' Opinion:- [By ]
Buy, sell, or hold? (Free preview) TSRO is building up for a major improvement in its outlook. After a year and a half of decline to levels even below their historic NOVA trial results, this is getting ridiculous. To me, it is clear that TSRO is undervalued, and it is poised well for a positive catalyst. Whether that comes in the form of improving sales or the rumored Roche (OTCQX:RHHBY) buyout, I think it points north from here for TSRO. You should definitely consider a buy as soon as you can, because we're probably going to see this company at least 20% higher within 6 months, barring any unforeseen bad turn of events.
- [By Todd Campbell]
Investors should also keep their enthusiasm in check because Loxo Oncology isn't alone in targeting TRK fusion and RET mutations:�Roche Holdings (NASDAQOTH:RHHBY) could challenge it in TRK fusions and Blueprint Medicines (NASDAQ:BPMC) could compete with it in RET mutations.�
- [By Cory Renauer]
Regeneron's revenue stream is awfully lopsided with U.S. sales of its blockbuster eye drug generating 65% of total revenue. The eyeball injection that slows down top causes of blindness among older adults could face some competition from Novartis' (NYSE:NVS) brolucizumab or�Roche's (NASDAQOTH:RHHBY) RG7716, two candidates in late-stage development.
- [By Todd Campbell]
After announcing that Roche Holdings (NASDAQOTH:RHHBY) will acquire it for $137 per share in cash, shares in Foundation Medicine (NASDAQ:FMI) are soaring 28.3% at 11:30 a.m. EDT today.
- [By ]
The two currently approved treatments are Esbriet (pirfenidone) from the Roche Group (OTCQX:RHHBY), and OFEV (nintedanib) from Boehringer Ingelheim, both of which were approved for IPF in Oct. 2014. In their respective pivotal trials, both drugs were shown to slow the loss of the patients' respiratory function, as measured by the forced vital capacity (FVC(ml)).
Hot Casino Stocks To Invest In Right Now: AltaGas Ltd. (ATGFF)
Advisors' Opinion:- [By ]
AltaGas (OTCPK:ATGFF) agreed to acquire WGL (WGL) in January 2017, and the acquisition is still pending regulatory approval in DC, which is expected mid-2018. WGL operates Washington Gas, the gas utility in the region. The interesting play here I think is AltaGas. It offers a fairly well covered 8.5%+ dividend but has been beaten down as a result of concerns over the price paid for the WGL acquisition and the debt it will be required to take on in the deal. If the WGL acquisition does not receive regulatory approval, it's very possible that AltaGas goes up. And if WGL is approved, it's obviously a much better acquisition if Amazon picks anywhere in the DC area, as that should fuel a significant population increase for the gas utility business (some estimates of up to 1 million over 10 to 15 years). The projected growth in the gas utility business can serve as the foundation for AltaGas's broader operations and allow them to finance debt at more attractive levels going forward. A mere re-rating to a market AFFO multiple would lead to substantial gains from the current 10-20% discount to market AFFO multiples, and a premium driven by the growth in Washington Gas could warrant a 10-20% premium to market AFFO multiples.
Hot Casino Stocks To Invest In Right Now: Becton, Dickinson and Company(BDX)
Advisors' Opinion:- [By Joseph Griffin]
Traders sold shares of Becton Dickinson and Co (NYSE:BDX) on strength during trading hours on Tuesday. $46.93 million flowed into the stock on the tick-up and $88.54 million flowed out of the stock on the tick-down, for a money net flow of $41.61 million out of the stock. Of all equities tracked, Becton Dickinson and had the 30th highest net out-flow for the day. Becton Dickinson and traded up $1.07 for the day and closed at $233.64
- [By Joseph Griffin]
McQueen Ball & Associates Inc. decreased its holdings in shares of Becton Dickinson and Co (NYSE:BDX) by 1.9% in the second quarter, Holdings Channel reports. The firm owned 15,033 shares of the medical instruments supplier’s stock after selling 295 shares during the quarter. Becton Dickinson and makes up 2.2% of McQueen Ball & Associates Inc.’s investment portfolio, making the stock its 8th biggest position. McQueen Ball & Associates Inc.’s holdings in Becton Dickinson and were worth $3,601,000 at the end of the most recent reporting period.
- [By Logan Wallace]
Evergreen Capital Management LLC grew its holdings in shares of Becton Dickinson (NYSE:BDX) by 12.8% in the first quarter, according to its most recent filing with the SEC. The firm owned 15,558 shares of the medical instruments supplier’s stock after acquiring an additional 1,768 shares during the quarter. Evergreen Capital Management LLC’s holdings in Becton Dickinson were worth $3,371,000 as of its most recent SEC filing.
- [By Brian Orelli]
Becton, Dickinson (NYSE:BDX) reported wacky results for its second fiscal quarter.�This is the first quarter that the medical supply company has included results from its�acquisition�of�C.R. Bard. But looking at the two companies on a comparable basis, it was a solid quarter for the newly combined company.
- [By Keith Speights]
Dividend Yield
Abbott Laboratories (NYSE:ABT) Drugs $109 billion 19.37 1.88% AstraZeneca (NYSE: AZN) Drugs $93 billion 19.70 3.97% Becton Dickinson and Co. (NYSE: BDX) Medical supplies $60 billion 17.74 1.29% DexCom (NASDAQ: DXCM) Medical devices $8 billion N/A N/A Eli Lilly and Co. (NYSE: LLY) Drugs $85 billion 14.91 2.77% Insulet (NASDAQ: PODD) Medical devices $5 billion 273.03 N/A Johnson & Johnson (NYSE: JNJ) Drugs, medical devices $325 billion 14.16 2.57% Lexicon Pharmaceuticals (NASDAQ:LXRX) Drugs $1 billion N/A N/A MannKind (NASDAQ: MNKD) Drugs $270 million N/A N/A Medtronic (NYSE: MDT) Medical devices $117 billion 15.36 2.14% Merck & Co. (NYSE: MRK) Drugs $159 billion 12.99 3.22% Novo Nordisk (NYSE:NVO) Drugs $116 billion 18.29 2.61% Pfizer (NYSE: PFE) Drugs $209 billion 11.62 3.82% Regeneron Pharmaceuticals (NASDAQ: REGN) Drugs $32 billion 13.95 N/A Sanofi (NYSE: SNY) Drugs $95 billion 10.75 4.64% Senseonics Holdings (NYSEMKT: SENS) Medical devices $447 million N/A N/A Tandem Diabetes Care (NASDAQ: TNDM) Medical devices $711 million N/A N/AData source: Yahoo! Finance. P/E = price-to-earnings ratio; N/A = not applicable. Data as of May 25, 2018.
Hot Casino Stocks To Invest In Right Now: Stoneridge Inc.(SRI)
Advisors' Opinion:- [By Ethan Ryder]
Shares of Stoneridge, Inc. (NYSE:SRI) have earned a consensus rating of “Buy” from the nine research firms that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $31.40.
- [By Shane Hupp]
Stoneridge (NYSE: SRI) and LCI Industries (NYSE:LCII) are both computer and technology companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership and analyst recommendations.
- [By Joseph Griffin]
SG Americas Securities LLC bought a new stake in Stoneridge, Inc. (NYSE:SRI) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 4,108 shares of the auto parts company’s stock, valued at approximately $113,000.
No comments:
Post a Comment